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Aims: The study was planned to compare Anti-thrombotic strategies for patients under-
going PCI in a real world population with an emphasis on occurrence of major bleeding,
composite ischemic end points and economic outcomes.
Methods: The present study is a single center, prospective, observational study in consecutive
patients undergoing PCI at Fortis Escorts Heart Institute (FEHI) and describes Authors' expe-
rience with three different Anti-Thrombotic Strategies in a real world population. Patients
were consecutively enrolled in the studyand thechoiceofAnti-thrombotic strategywas left to
individual operator(s) based on their own clinical judgment and patient's affordability. No
specific inclusion/exclusion criteriawere specified on the choice of Anti-Thrombotic Strategy.
Results: A total 1453 patients were consecutively enrolled into the study and were followed
telephonically after 30 days. 252 patients were treated with Bivalirudin (Angiomax) during
PCI (17.3%), 430 (29.6%) patients were treated with Heparin plus GPI & remaining 771 (53.1%)
were treated with Heparin monotherapy. Incidence of major bleeding was lowest in patients
treated with Bivalirudin (1.59%) when compared to Heparin plus GPI (3.49%) and Heparin
monotherapy (5.97%), p ¼ 0.005 Bivalirudin vs. Heparin Monotherapy, and p ¼ 0.145, Biva-
lirudin vs. Heparin þ GPI. No bleeding was observed in STEMI patients treated withIGHT HORIZONS for Bivalirudin? EUROMAXimizing benefits of bleeding risk but catching a
8; fax: þ 91 11 26825013.
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i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 3 1 1e3 1 7312Bivalirudin compared to 7.4% in patients treated with GPI and 14.3% in patients treated with
UFH. Similarly non-access site bleeding was lowest in patients treated with Bivalirudin. Only
4 patients (1.6%) treated with Bivalirudin required Blood transfusion compared to 25 in
Heparin plus GPI (5.8%) and 38 (5%) in Heparin Monotherapy arm. In Composite Ischemic
end-points, no “All-cause Mortality” was observed in Bivalirudin group compared to 2.8% in
Heparin plus GPI. Early stent thrombosis was seen in 1 patient with Heparin plus GPI and
none with Heparinmonotherapy and Bivalirudin group. None of the patients underwent TLR
(target lesion revascularization) and TVR (target vessel revascularization) within 30 days post
procedure other than one early stent thrombosis reported with Heparin plus GPI. Cost of
blood product transfusion was lower with Bivalirudin as compared to Heparin plus GP IIb/IIIa
arm (p¼ 0.01) and with Heparin alone (p¼ 0.001). Due to lower complications including blood
transfusions and reduced hospital stay in Bivalirudin group, these benefits outweigh the
incremental cost due to higher acquisition cost of the drug.
Conclusion: Bivalirudin use during PCI is associated with a distinct advantage of having
lower access site and non-access site bleeding without compromising on the efficacy. We
observed a reduction in blood transfusions, hospital stay and mortality for patients treated
with Bivalirudin compared with Heparin plus GPI or Heparin Monotherapy. Bivalirudin can
be safely adopted into our Institutional protocol for the treatment of high risk PCI such as
STEMI, ACS, and Complex elective PCI.
Copyright © 2015, Cardiological Society of India. All rights reserved.1. Introduction
Anti-coagulation during PCI is very important to the out-
comes. Heparin, Heparin plus GPI and Bivalirudin are the
currently used Anti-coagulation strategies. Randomized clin-
ical trials and various meta-analyses have shown that Direct
Thrombin Inhibitor Bivalirudin significantly reduces bleeding-
related complications in patients undergoing PCI.1e5 Based on
this evidence, Bivalirudin has received a class I recommen-
dation as anticoagulant for PCI.6,7 From an Indian perspective,
there is an inherent dearth of data in ACS patients undergoing
invasive therapy with different anti-thrombotic management
outcomes. There have been no published studies in India that
have been conducted to understand the different anti-
thrombotic managements outcomes in terms of frequent
hemorrhagic complications and the cost involved in such
management. Data from various registries have shown that
ACS patients in India tend to be young, from low socio-
economic groups, have a higher rate of STEMI than patients
in developed countries. They receive delayed medical atten-
tion and proven therapies less often and have higher 30-day
mortality than high socio-economic groups.8 Hence, evi-
dence concerning the benefits of the many potential anti-
thrombotic agents in terms of hemorrhagic complications
and the cost incurred for such managements used in a real-
life setting is lacking. We chose to study the impact of
different Anti-thrombin strategies at a high volume Tertiary
Care center in a real world population to generate evidence
and future directions.2. Methods
The present study is a single center, prospective, observa-
tional study in consecutive patients undergoing PCI at FortisEscorts Heart Institute (FEHI) and captures authors' experience
with three different Anti-Thrombotic Strategies in an all
comer patient population. The Institutional Ethics Committee
(IEC) approval was obtained prior to initiation of the study.
1450 patients were consecutively enrolled between June
2013eDec 2013 and the choice of Anti-thrombotic strategy
was left to individual operator(s) based on their own clinical
judgment and patient's affordability. No specific inclusion/
exclusion criteria were specified on the choice of Anti-
Thrombotic Strategy.3. Study protocol
Patients who underwent PCI were divided into 3 cohorts
depending on the Anti-thrombotic treatment. First group
received Bivalirudin as intravenous bolus of 0.75 mg/kg, fol-
lowed by an infusion of 1.75 mg/kg/hour. Our institutional
protocol requires us to continue the Bivalirudin infusion post
procedure at aminimumof running the entire bag out. Second
group was administered Heparin plus a Glycoprotein IIb/IIIa
Inhibitor (GPI) as per the standard hospital guidelines. Third
group was administered Unfractionated Heparin Mono-
therapy (UFH) as an intravenous bolus of 60 IU/kilogram of
bodyweight, with subsequent boluses targeted to an activated
clotting time (ACT) of >300 s. The Anti-platelet regimen was
given according to the hospital protocol.
Patients more than 18 years old were enrolled into the
study based on the following eligibility criteria:3.1. Inclusion criteria
The clinical classification of patients was done according to
recent ACC/AHA Guidelines.9
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a) ST-segment elevation of 1 mm in 2 contiguous leads;
or
b) Presumably new left bundle branch block (LBBB); or
c) True posterior myocardial infarction (MI) with ST
depression of 1 mm in 2 contiguous anterior leads.
2) NSTEMI/Unstable angina.
3) Chronic stable angina.
4) Written informed consent.3.2. Exclusion criteria
1) Contraindication to any of the study medications.
2) Prior administration of thrombolytic therapy, Bivalirudin,
GPI, LMWH or Fondaparinux (Factor Xa Inhibitor) for the
present admission (prior UFH allowed).
3) Current use of Coumadin.
4) History of bleeding diathesis or known coagulopathy
(including HIT)
5) History of Intracerebral Mass, Aneurysm, Arteriovenous
Malformation (AVM), or hemorrhagic stroke; stroke or
transient ischemic attacks (TIA) within 6 months or any
permanent neurologic deficit; gastrointestinal (GI) or
genitourinary (GU) bleedwithin 2months, ormajor surgery
within 6 weeks; recent or known platelet count <100,000
cells/mm3 or hgb <10 g/dL.
Data from patients from all three arms was collected pro-
spectively during hospital stay and then through 30 day tele-
phonic follow up. Following analysis was done-
1) Major Bleeding (not related to CABG) was defined as:
 Any intracranial bleeding (excluding microhemorrhages
<10 mm evident only on gradient-echo MRI)
 Clinically overt signs of hemorrhage associated with a
drop in hemoglobin of 5 g/dL or a 15% absolute
decrease in hematocrit
 Fatal bleeding (bleeding that directly results in death
within 7 d)
2) Composite end point, defined as all cause death, myocar-
dial infarction, unplanned revascularization for ischemia
within 30 days.
3) Cost Analysis e in the form of days in hospitalization after
PCI. Special treatment required in the form of surgical in-
terventions and blood transfusions were also considered
for cost analysis.
Stent thrombosis was defined according to the Academic
Research Consortium.10 Myocardial re-infarction was defined
to have occurred, if 2 of the following 5 criteria were present:Table 1 e Treatment arms and patient distribution.
Group Treatment protocol
Bivalirudin Patients who were being managed with Bivalirudin
Heparinþ
GPI
Patients who were being managed with Heparin plu
infusion
Heparin Patients who were being managed with Heparin aloni. chest pain lasting longer than 30 min;
ii. substantial changes on ECG that were typical of acute
myocardial infarction (an ST-segment elevation of
0.1 mV in at least 2 adjacent ECG leads or the new
occurrence of a complete left bundle-branch block);
iii. a substantial increase in the level of CK-MB isoform (at
least 3 times the upper normal value);
iv. new, clinically significant Q waves; and
v. chest pain leading to angiography up to 6 h after the
onset of the pain, with angiographic evidence of a
totally occluded vessel.4. Statistical analysis
Descriptive analysis was carried out. Categorical variables
were presented in number and percentage (%) and continuous
variables presented as mean ± standard deviation (SD). Be-
tween groups, comparison was performed by applying conti-
nuity corrected chi-squared statistic of Fisher's exact test for
categorical data. Analysis of variance (ANOVA) was carried
out for comparison of group mean. A Two-proportion Z test
was used to analyze the cost effectiveness. Statistical signifi-
cance was assumed at a value of p ¼ 0.05. All statistical ana-
lyses was performed with SPSS for windows (version 13.0).5. Results
A total of 1453 patients were enrolled into this study. 17.3%
were in Bivalirudin arm, 29.6% received Heparin plus GPI and
53.1% were administered Heparin Monotherapy (Table 1).
Mean age in Bivalirudin, Heparin plus GPI & Heparin arm
were 61.1 ± 11.02 years, 59.5 ± 10.0 and 61.3 ± 10.9 years,
respectively. In all the three treatment groups, mean age was
statistically similar (Bivalirudin and Heparin plus GPI; p¼ 0.37,
Bivalirudin and Heparin; p ¼ 0.669, Heparin plus GPI and
Heparin; p ¼ 0.85).
Table 2 shows demography and baseline clinical charc-
teristics of the enrolled patients. The number of males was
significantly higher in GPI arm (97.2%). There were 80.4%
males in Heparin arm and 77.8% in Bivalirudin arm (p¼ 0.342).
Bivalirudin arm had more diabetic patients (46.6%) than
Heparin plus GPI (12.09%; p ¼ 0.0001) but were comparable
between Bivalirudin and Heparin (41.1%, p ¼ 0.07). There were
less hypertensive patients in GPI cohort, but it did not reach
statistical significance (p ¼ 0.524). Table 3 summarizes the co-
morbid conditions for these patients. Clopidogrel was the
most common anti-platelet used. Newer anti-platelet drugs
Prasugrel & Ticagrelor were used more in Bivalirudin 37.7% (p
value ¼ 0.0001) and 15.8% (p value ¼ 0.0001), respectivelyNo. of patients Percentage
252 17.3%
s GPI, either bolus or 430 29.6%
e 771 53.1%
Table 2 e Demographics and baseline clinical characteristics.
Variable Bivalirudin (n ¼ 252) HeparinþGPI(n ¼ 430) Heparin (n ¼ 771) Statistical significance









c2 ¼ 72.6 p ¼ 0.0001 (S)
History of Diabetes Mellitus 120 (47.6%) 52 (12.09%) 317 (41.11%) c2 ¼ 130.7 p < 0.0001 (S)
History of Hypertension 152 (60.31%) 272 (61.16%) 462 (59.9%) c2 ¼ 1.34 p ¼ 0.510 (NS)
ACS 242 (94%) 422 (98.1%) 699 (90.7%) c2 ¼ 1.8; p ¼ 0.405 (NS)
Clopidogrel 119 (47.2%) 350 (81.4%) 656 (85.1%) c2 ¼ 161.; p ¼ 0.000(S)
Prasugrel 95 (37.7%) 74 (17.2%) 96 (12.4%) c2 ¼ 816; p ¼ 0.0001 (S)
Ticagrelor 38 (15.1.%) 6 (1.4%) 19 (2.5%) c2 ¼ 85.6.; p ¼ 0.0001 (S)
Table 3 e Co-morbid conditions.
Arm Diabetes Non-diabetics HTN Non-HTN Total
Bivalirudin 120 (47.6%) 132 152 (60.31%) 100 252
Heparin þ GPI 52 (12.09%) 378 272 (61.6%) 158 430
Heparin 317 (41.11%) 454 462 (59.9) 309 771
HTN: Hypertension.
Fig. 1 e Distribution of patients with angina and ACS.
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were having ACS (93.8%) with Unstable Angina (UA) being the
leading indication for PCI (Fig. 1). Stable angina patients un-
dergoing PCI were more in Heparin arm (9.3%) than other 2
groups (Table 5). STEMI patients were more in Bivalirudin
treatment arm and Heparin plus GPI group when compared
withHeparin alone. STEMI patientswere similar in Bivalirudin
(19.4%) as compared to Heparin plus GPI (21.9%; p ¼ 0.454).
Major Bleeding was 1.59% in Bivalirudin arm; 3.49% in
Heparin plus GPI and 5.97% in Heparin arm with statistically
significant bleeding with Heparin versus Bivalirudin
(p ¼ 0.005). There was no statistically significant difference in
bleeding between Bivalirudin and Heparin plus GPI (p ¼ 0.145).
There was no bleeding observed in STEMI patients treated
with Bivalirudin compared to 7.4% in STEMI patients treated
with GPI and 14.3% in STEMI patients treated with UFH. Table
6 summarizes bleeding incidences in various groups.
Composite End Point, (all cause death, myocardial infarc-
tion unplanned revascularization for ischemia within 30
days).
30 Day Mortality: All-cause mortality within 30 days was
2.8% in Heparin plus GPI cohort and none in Heparin and
Bivalirudin alone treatment arm.
Stent Thrombosis: Early definite stent thrombosis was
seen in 1 patient who was on Heparin plus GPI. There was no
case reported in Heparin group and Bivalirudin alone.
TLR and TVR within 30 days: None of the patients under-
went TLR& TVRwithin 30 days post procedure other than one
early stent thrombosis reported with Heparin plus GPI.Table 4 e Anti-platelet use.
Treatment arm Clopidogrel P
Bivalirudin 119 (47.2%) 9
Heparin þ GPI 350 (81.4%) 7
Heparin 656 (85.1%) 9Unplanned Revascularization: No Unplanned Revascular-
ization was observed in any group.
Cost Analysis: Mean Cost of blood product transfusions
was INR 111.11 in Bivalirudin treated group, INR 308.98 with
Heparin plus GPI and INR 373.54 with Heparin alone. Cost of
blood product transfusion was lower with Bivalirudin as
compared to Heparin plus GP IIb/IIIa arm (p ¼ 0.01) and with
Heparin alone (p ¼ 0.001). After adding the acquisition cost of
anti-thrombotic therapy and stay in hospital, the treatment
cost increased to INR 16, 693with Bivalirudin alone, INR 10,440
with Heparin plus GPI and INR 1307 with Heparin alone (Table
7). The benefits on account of lesser blood transfusion and
reduced hospital stay still outweigh the incremental costs of
drug acquisition.rasugrel Ticagrelor Total
5 (37.7%) 38 (15.8%) 252
4 (17.2%) 6 (1.4%) 430
6 (12.4%) 19 (2.5%) 771
Table 5 e Patient distribution based on clinical condition.
Condition Bivalirudin HeparinþGPI Heparin Chi square p value
Stable angina 10 (4.00%) 6 (1.40%) 72(9.30%) 28.8 <0.001
STEMI 49 (19.40%) 94 (21.90%) 105 (13.60%) 12.57 0.001
NSTEMI 7 (2.80%) 23 (5.30%) 24 (3.10%) 4.43 0.1
Unstable angina 140 (55.60%) 242 (56.30%) 570 (73.90%) 17.74 0.0001
Table 6 e Bleeding incidences.
Treatment groups Bivalirudin HeparinþGPI Heparin p value
Major bleeding 4 (1.59%) 3.15 (3.49%) 46 (5.97%) <0.005
Major bleeding in STEMI patients 0 (0%) 7 (7.40%) 7 (14.3%) <0.001
Access site bleeding 2 (0.79%) 7 (1.63%) 23 (2.98%) 0.1
Non access site bleeding 2 (0.79%) 8 (1.86%) 23 (2.98%)
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Bivalirudin (Angiomax) was launched by Medicines Company
in USA in 2001. However it wasmade available in India only in
late 2011. Most of the published clinical trials have compared
Bivalirudin with Heparin plus GPI and the results have been
shown to be largely in favor of Bivalirudin both for In-hospital
outcomes as well as long term benefits. The economic anal-
ysis from larger registry data base in US and also some large
randomized trials also point out the economic benefit of using
Bivalirudin in PCI. Recently published meta-analysis has
shifted the focus of comparing the Bivalirudin outcomes
against Heparin Monotherapy. All these data has been
generated in a Western Healthcare system which works very
differently compared to an Indian Healthcare System. The
present study was carried out with an aim to compare anti-
thrombotic strategy adopted at a tertiary care hospital in
New Delhi. We compared the outcomes in an all comer pop-
ulation of patients undergoing PCI with Bivalirudin, Heparin
plus GPI and Heparinmonotherapy. This reflects a true Indian
settingwhere there aremultiple factors that govern the choice
of drugs used in PCI. We also compared our data with some
other published studies and registries and found it compara-
ble to studies like ACTION registry,11 Rassen et al.12 We found
mean age in Bivalirudin arm was 61.1 years, 59.5 years in
Heparin plus GPI arm and 61.3 years in Heparin alone arm
which were statistically similar in all the arms. Moreover, it
was observed that 47.6% patients in Bivalirudin arm were
diabetic. This was more when compared to UFH (41.1%) and
GPI (12%). In addition, there were more male diabetic patientsTable 7 e Cost effectiveness analysis.
Bivali
Mean cost of blood product transfusions (INR)
Cost incurred after adding anti thrombotic therapy
Number of blood transfusion
Percentage of blood transfusion (%)
Cost of treatment per patient requiring blood transfusion
Total cost per patient with anti thrombin and blood transfusion
Cost comparison Bivalirudin vs. Heparin þ GPI Z ¼ 2
Cost comparison Bivalirudin vs. Heparin Monotherapy Z ¼ 3in each arm compared to female diabetic patients. Hyperten-
sion was seen in 61.16% in Heparin plus GPI arm, 59.9% in
Heparin arm and 60.31% in Bivalirudin arm.
In Heparin group, 85.1% patients were on Clopidogrel
while in Bivalirudin group, 47.2% were on Clopidogrel. The
EUROMAX13 study comparing Bivalirudin with Heparin and
optional GPI in STEMI patients reflected the change in use of
anti-platelet agents. In EUROMAX, almost 50% of the pa-
tients were treated with Prasugrel or Ticagrelor and 50% of
the patients received clopidogrel both in Bivalirudin arm as
well as Heparin with optional GPI. In our study, 37.7% and
15.1% patients were treated with Prasugrel and Ticagrelor
respectively in Bivalirudin arm and 12.4% and 2.5% in Hep-
arin arm. In EUROMAX study Prasugrel was used in 33.5% in
Bivalirudin arm and 30.8% in Heparin with optional GPI.
Ticagrelor was used in 26.9% in Bivalirudin arm and 26.7% in
Heparin with optional GP IIb/IIIa inhibitor. This reflects an
early stage of adoption of newer Anti-platelet drug in our
Institute.
Major bleeding was reported as 1.59% in Bivalirudin arm,
3.49% in Heparin plus GPI and 5.97% in Heparin arm. Access
site bleeding was 0.79% in Bivalirudin treatment group, 1.62%
in Heparin plus GPI and 2.98% in Heparin arm. This repre-
sented an absolute reduction of 4.5% bleeding with Bivalirudin
compared to UFH and an absolute reduction of 2% compared
to GPI. The relative risk reduction was 73% compared to UFH
and 54% compared to GPI. In addition, the patients on UFH
required more blood transfusions compared to the patients
who were on Bivalirudin thus resulting in more cost effec-
tiveness of using an ‘expensive’ Bivalirudin. In current study,







.25; p value ¼ 0.01
.23; p value ¼ 0.001
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 3 1 1e3 1 7316bleeding including access site and non-access site bleeding
with Bivalirudin as compared to Heparin with or without GPI
is consistent with the literature.14 Though, these results are
contrary to the results of HEAT-PPCI study that suggested
bleeding rates of Heparin alone are not different from those of
Bivalirudin.15 All-cause mortality within 1 month was 2.8% in
Heparin plus GPI, 0.1% in Heparin, There was no death re-
ported in Bivalirudin. Early definite stent thrombosis was seen
in one patient in Heparin plus GPI, and none in Heparin alone
arm. In EUROMAX study, definite stent thrombosis was seen
in 1.6% cases in Bivalirudin arm and 0.2% in Heparin with
optional GPI. In EUROMAX trial, patients treated with Bivalir-
udin were at higher risk for acute stent thrombosis, an
observation consistent with the results of HORIZONS-
AMI.16e18 The increased risk for acute stent thrombosis was
limited to the first 4 h after the index procedure and was
probably the result of the combination of the short half-life
and rapid clearance of Bivalirudin and the delayed bioavail-
ability of the oral P2Y12 inhibitors, including the newer agents
Prasugrel and Ticagrelor. Another reason for higher stent
thrombosis in EUROMAX study was the lower dose of Biva-
lirudin infusion (0.25 mg/kg/hour) post procedure. In FEHI, we
give a regular PCI dose infusion of Bivalirudin and run the bag
out. A recent study from China BRIGHT19 using similar Biva-
lirudin protocol also did not show increase in stent throm-
bosis while maintaining lower bleeding rates.
Possible treatments that couldmitigate the reported risk of
stent thrombosis could include co-administration of UFH,
prolongation of the Bivalirudin infusion at the PCI dose for the
first few hours after the procedure, or the use of an immediate
acting P2Y12 inhibitor such as Cangrelor; however, they will
need to be tested in prospective trials. In our study none of the
patients underwent TLR & TVR within 30 days post procedure
other than one early stent thrombosis reported with Heparin
plus GP IIb/IIIa inhibitors.
Mean cost of blood product transfusions was INR 111.11
in Bivalirudin treatment group, INR 308.98 with Heparin plus
GPI and INR 373.54 with Heparin alone. Initial cost of blood
product transfusion was lower with Bivalirudin when
compared to Heparin plus GPI arm. But, after adding, the
acquisition cost of anti-thrombotic therapy and stay in
hospital, the treatment cost increased to INR 16, 693 with
Bivalirudin, INR 10, 440 with Heparin plus GPI and INR 1307
with Heparin alone. Though the cost of Bivalirudin increases
the cost of overall cost of treatment, the benefits on account
of lesser blood transfusion and reduced hospital stay still
outweigh the incremental costs of drug acquisition.7. Limitations
The study was a single centre study and open label study.
Additional data to show the cost effectiveness of Bivalirudin in
Stable angina patients should be generated and analyzed.
Long term benefit of newer Anti-Thrombotic agents should be
further evaluated. The practice patterns at other Indian in-
stitutions may not necessarily represent practice patterns at
FEHI.8. Conclusion
Use of Bivalirudin in all elective PCI should be considered and
further data needs to be analyzed/generated. Bivalirudin can
be safely adopted into Institutional protocol for the treatment
of high risk PCI such as STEMI, ACS and complex elective PCI.
Bivalirudin use during PCI is associated with a distinct
advantage of having lower access site and non-access site
bleeding without compromising on the overall efficacy. There
was a reduction in number of blood transfusions, hospital stay
and in short-term mortality for patients treated with Bivalir-
udin compared with Heparin plus GP IIb/IIIa inhibitors. The
lower peri-procedural myocardial damage rates associated
with PCI in the Bivalirudin group would improve outcomes in
patients undergoing high risk PCI. Use of newer anti-platelet
drugs should be encouraged in a real world setting with
Bivalirudin.Conflicts of interest
The authors have none to declare.r e f e r e n c e s
1. Lincoff AM, Bittl JA, Harrington RA, et al, for REPLACE-2
Investigators. Bivalirudin and provisional glycoprotein
IIb/IIIa blockade compared with Heparin and planned
glycoprotein IIb/IIIa blockade during percutaneous coronary
intervention: REPLACE-2 randomized trial. JAMA.
2003;289:853e863.
2. Stone GW, McLaurin BT, Cox DA, et al, for ACUITY
Investigators. Bivalirudin for patients with acute coronary
syndromes. N Engl J Med. 2006;355:2203e2216.
3. Bertrand OF, Jolly SS, Rao SV, et al. Meta-analysis comparing
Bivalirudin versus Heparin monotherapy on ischemic and
bleeding outcomes after percutaneous coronary intervention.
Am J Cardiol. 2012;110:599e606.
4. Tarantini G, Brener SJ, Barioli A, et al. Impact of baseline
hemorrhagic risk on the benefit of Bivalirudin versus
unfractionated Heparin in patients treated with coronary
angioplasty: a meta-regression analysis of randomized trials.
Am Heart J. 2014;167:401e412. e6.
5. Nairooz R, Sardar P, Amin H, et al. Meta-analysis of
randomized clinical trials comparing Bivalirudin versus
heparin plus glycoprotein IIb/IIIa inhibitors in patients
undergoing percutaneous coronary intervention and in
patients with ST-segment elevation myocardial infarction.
Am J Cardiol. 2014;114:250e259.
6. Levine GN, Bates ER, Blankenship JC, et al, American College
of Cardiology Foundation; American Heart Association Task
Force on Practice Guidelines; Society for Cardiovascular
Angiography and Interventions. 2011 ACCF/AHA/SCAI
guideline for percutaneous coronary intervention. A report of
the American College of Cardiology Foundation/American
Heart Association Task Force on Practice Guidelines and the
society for cardiovascular angiography and interventions.
J Am Coll Cardiol. 2011;58:e44e122.
7. Wijns W, Kolh P, Danchin N, et al, Task Force on Myocardial
Revascularization of the European Society of Cardiology (ESC)
and the European Association for Cardio-Thoracic Surgery
(EACTS); European Association for Percutaneous
i n d i a n h e a r t j o u rn a l 6 7 ( 2 0 1 5 ) 3 1 1e3 1 7 317Cardiovascular Interventions (EAPCI). Guidelines on
myocardial revascularization. Eur Heart J. 2010;31:2501e2555.
8. Xavier D, Pais P, Devereaux PJ, et al. Treatment and outcomes
of acute coronary syndromes in India (CREATE) : a
prospective analysis of registry data. Lancet.
2008;171:1435e1442.
9. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA
guideline update for the management of patients with
unstable angina and non-ST-segment elevation myocardial
infarction d 2002: summary article: a report of the American
College of Cardiology/American Heart Association Task Force
on Practice Guidelines (Committee on the Management of
Patients with Unstable Angina). Circulation. 1893-900;002:106.
10. Donald E, Cutlip MD, Stephan Windecker MD, et al. Clinical
end points in coronary stent trials, a case of standardised
definition. Circulation. 2007;115:2334e2351.
11. Lopes RD, Peterson ED, Chen AY, et al. Antithrombotic
strategy in NoneST-segment elevation myocardial infarction
patients undergoing percutaneous coronary intervention:
insights from the ACTION (Acute coronary treatment and
intervention outcomes Network) registry. J Am Coll Cardiol
Intv. 2010;3:669e677.
12. Rassen JA, Mittleman MA, Glynn RJ, et al. Safety and
effectiveness of Bivalirudin in routine care of patients
undergoing percutaneous coronary intervention. Eur Heart J.
2010;31:561e572.
13. Steg PG, van't Hof A, Clemmensen P, et al. Design and
methods of European Ambulance Acute Coronary Syndrome
Angiography Trial (EUROMAX): an international randomized
open-label ambulance trial of bivalirudin versus standard-of-
care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary
percutaneous coronary intervention. Am Heart J. 2013
Dec;166:960e967.
14. Manoukian SV, Feit F, Mehran R, et al. Impact of major
bleeding on 30-day mortality and clinical outcomes in
patients with acute coronary syndromes: an analysis from
the ACUITY Trial. J Am Coll Cardiol. 2007;49:1362e1368.
15. Shahzad A, Kemp I, Mars C, et al. Unfractionated heparin
versus bivalirudin in primary percutaneous coronary
intervention (HEAT-PPCI): an open-label, single centre,
randomised controlled trial. Lancet; 2014. published online
July 4 http://dx.doi.org/10.1016/S0140-6736(14)60924-7.
16. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin
during primary PCI in acute myocardial infarction. N Engl J
Med. 2008;358:2218e2230.
17. Mehran R, Lansky AJ, Witzenbichler B, et al. Bivalirudin in
patients undergoing primary angioplasty for acute
myocardial infarction (HORIZONS-AMI): 1-year results of a
randomised controlled trial. Lancet. 2009 Oct 3;374:1149e1159.
18. Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a
glycoprotein IIb/IIIa inhibitor versus Bivalirudin monotherapy
and paclitaxel-eluting stents versus bare-metal stents in
acute myocardial infarction (HORIZONS-AMI): final 3-year
results from a multicentre, randomised controlled trial.
Lancet. 2011;377:2193e2204.
19. Han Yaling, Guo Jincheng, Zheng Y, et al. Bivalirudin vs
heparin with or without tirofiban during primary
percutaneous coronary intervention in acute myocardial
infarction: the BRIGHT randomized clinical trial. JAMA.
2015;313:1336e1346. http://dx.doi.org/10.1001/
jama.2015.2323.
